Long-term survival is possible with aggressive treatment. The prognosis of AML patients with genetic mutations and chromosomal changes is indicative of disease prognosis, which is poorer in those with secondary radiotherapy or myelodysplastic syndromes/chronic myeloproliferative neoplasms, combined with extramedullary leukaemia.